CL2012002016A1 - Vector para vacunas que comprende un polipeptido antigénico y un polipéptido hmgb1 o un fragmento funcional; composición que comprende el vector; método para potenciar respuesta inmune en un sujeto. - Google Patents
Vector para vacunas que comprende un polipeptido antigénico y un polipéptido hmgb1 o un fragmento funcional; composición que comprende el vector; método para potenciar respuesta inmune en un sujeto.Info
- Publication number
- CL2012002016A1 CL2012002016A1 CL2012002016A CL2012002016A CL2012002016A1 CL 2012002016 A1 CL2012002016 A1 CL 2012002016A1 CL 2012002016 A CL2012002016 A CL 2012002016A CL 2012002016 A CL2012002016 A CL 2012002016A CL 2012002016 A1 CL2012002016 A1 CL 2012002016A1
- Authority
- CL
- Chile
- Prior art keywords
- vector
- polypeptide
- subject
- composition
- immune response
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 2
- 108090000765 processed proteins & peptides Proteins 0.000 title 2
- 230000000890 antigenic effect Effects 0.000 title 1
- 239000012634 fragment Substances 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29709810P | 2010-01-21 | 2010-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012002016A1 true CL2012002016A1 (es) | 2014-06-20 |
Family
ID=44307229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012002016A CL2012002016A1 (es) | 2010-01-21 | 2012-07-20 | Vector para vacunas que comprende un polipeptido antigénico y un polipéptido hmgb1 o un fragmento funcional; composición que comprende el vector; método para potenciar respuesta inmune en un sujeto. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8956618B2 (enExample) |
| EP (1) | EP2525817B8 (enExample) |
| JP (3) | JP6242050B2 (enExample) |
| KR (1) | KR101638661B1 (enExample) |
| CN (1) | CN102811734B (enExample) |
| AU (1) | AU2011207331C1 (enExample) |
| CA (1) | CA2787661C (enExample) |
| CL (1) | CL2012002016A1 (enExample) |
| CO (1) | CO6561819A2 (enExample) |
| DK (1) | DK2525817T3 (enExample) |
| EA (1) | EA023058B1 (enExample) |
| ES (1) | ES2643646T3 (enExample) |
| HU (1) | HUE037157T2 (enExample) |
| MX (1) | MX341775B (enExample) |
| NO (1) | NO2525817T3 (enExample) |
| NZ (1) | NZ601609A (enExample) |
| PL (1) | PL2525817T3 (enExample) |
| PT (1) | PT2525817T (enExample) |
| UA (1) | UA110024C2 (enExample) |
| WO (1) | WO2011091255A1 (enExample) |
| ZA (1) | ZA201205824B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3097926T3 (pl) * | 2007-11-01 | 2020-04-30 | The Board Of Trustees Of The University Of Arkansas | Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria |
| HUE037157T2 (hu) | 2010-01-21 | 2018-08-28 | Univ Arkansas | Vakcinavektorok, és eljárások immunválaszok fokozására |
| KR102008120B1 (ko) | 2010-06-09 | 2019-08-07 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 캄필로박터 감염을 감소시키기 위한 백신 및 방법 |
| US20190263888A1 (en) | 2010-10-19 | 2019-08-29 | Op-T Llc | Therapeutic peptides and methods for treating autoimmune related disease |
| WO2012072788A1 (en) | 2010-12-02 | 2012-06-07 | Mab-Factory Gmbh | Vaccine against influenza h5n1 viruses, medicament and treatment of h5n1 viral infections |
| EA030929B1 (ru) * | 2013-02-14 | 2018-10-31 | Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас | КОМПОЗИЦИИ И СПОСОБЫ УСИЛЕНИЯ ИММУННЫХ ОТВЕТОВ НА Eimeria ИЛИ ОГРАНИЧЕНИЯ ИНФЕКЦИИ Eimeria |
| BR112015023024B1 (pt) | 2013-03-15 | 2022-04-19 | The Board Of Trustees Of The University Of Arkansas | Vetor de vacina e composições farmacêuticas compreendendo o mesmo |
| CN105399808B (zh) * | 2015-11-23 | 2019-05-10 | 青岛农业大学 | 一种许氏平鮋免疫增强蛋白hmgb1基因及编码蛋白和应用 |
| TWI758288B (zh) | 2016-05-03 | 2022-03-21 | 阿肯色州大學董事會 | 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法 |
| US11793854B2 (en) | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
| US11744875B2 (en) | 2019-07-12 | 2023-09-05 | Op-T Llc | Peptides and methods for treating disease |
| WO2021212013A2 (en) | 2020-04-17 | 2021-10-21 | Op-T Llc | Bioactive peptides and methods of use thereof |
| US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
| US12537071B1 (en) | 2020-07-22 | 2026-01-27 | David Gordon Bermudes | Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ285118B6 (cs) | 1991-03-05 | 1999-05-12 | The Wellcome Foundation Limited | Exprese rekombinačních proteinů v oslabených bakteriích |
| US7405270B2 (en) | 1991-10-25 | 2008-07-29 | Immunex Corporation | CD40-Ligand lacking native-pattern glycosylation |
| US5981724A (en) | 1991-10-25 | 1999-11-09 | Immunex Corporation | DNA encoding CD40 ligand, a cytokine that binds CD40 |
| DE69233051T2 (de) | 1991-10-25 | 2004-03-11 | Immunex Corp., Seattle | Antikörper gegen CD40-L |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| CA2143299A1 (en) | 1992-09-04 | 1994-03-17 | University Of Saskatchewan | Novel bacterial vaccines using vaccine strains of pathogenic bacteria |
| AU1059095A (en) | 1993-11-24 | 1995-06-13 | Australian National University, The | Treatment of viral disease with cd40l peptide |
| AU699291B2 (en) | 1995-03-01 | 1998-11-26 | Immunex Corporation | Method for stimulating an immune response |
| AU693713B2 (en) | 1995-06-07 | 1998-07-02 | Immunex Corporation | CD40L mutein |
| US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US6306387B1 (en) | 1997-05-29 | 2001-10-23 | The Research Foundation Of State University Of New York | Antigen delivery system |
| US20030045492A1 (en) | 1997-08-13 | 2003-03-06 | Tang De-Chu C. | Vaccination by topical application of recombinant vectors |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| CA2223225A1 (en) | 1997-11-28 | 1999-05-28 | Canadian Red Cross Society | Method for inhibiting in vivo immune response |
| JP2001526241A (ja) | 1997-12-19 | 2001-12-18 | イミュネックス・コーポレーション | Ｈｉｖ感染に対する感受性を低下させるための方法 |
| GB9806449D0 (en) | 1998-03-25 | 1998-05-27 | Peptide Therapeutics Ltd | Attenuated bacteria useful in vaccines |
| US6190669B1 (en) | 1998-05-13 | 2001-02-20 | University Of Maryland, Baltimore | Attenuated mutants of salmonella which constitutively express the Vi antigen |
| IT1299583B1 (it) | 1998-05-19 | 2000-03-16 | Vander Way Limited | Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica |
| PT1108034E (pt) | 1998-09-04 | 2008-11-14 | Emergent Product Dev Uk Ltd | Mutantes de spi2 de salmonela atenuados como transportadores de antigénios |
| US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
| EP1067194A1 (en) | 1999-04-16 | 2001-01-10 | F. Hoffmann-La Roche Ag | Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof |
| JP2003508016A (ja) | 1999-04-16 | 2003-03-04 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用 |
| US7118751B1 (en) | 1999-10-14 | 2006-10-10 | Trubion Pharmaceuticals, Inc. | DNA vaccines encoding antigen linked to a domain that binds CD40 |
| ES2222152T3 (es) | 1999-12-28 | 2005-02-01 | Akzo Nobel N.V. | Vacuna con las salmonellas que no inducen anticuerpos que reaccionan con la flagelina o los flagelos. |
| CA2399790C (en) | 2000-02-02 | 2012-10-30 | Ralph A. Tripp | Cd40 ligand adjuvant for respiratory syncytial virus |
| MXPA02008748A (es) | 2000-03-17 | 2003-02-24 | Upjohn Co | Materiales y metodos para vacuna antisalmonella. |
| GB0015426D0 (en) | 2000-06-24 | 2000-08-16 | Univ Southampton | Method for generating soluble highly multimeric proteins |
| EP1299115A2 (en) | 2000-06-26 | 2003-04-09 | Maxygen, Inc. | Methods and compositions for developing spore display systems for medicinal and industrial applications |
| WO2002036769A2 (en) | 2000-10-31 | 2002-05-10 | F. Hoffmann-La Roche Ag | Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof |
| HUP0500042A3 (en) | 2001-05-15 | 2010-01-28 | Long Island Jewish Res Inst | Use of hmg fragments as anti-inflammatory agents |
| EP2687593A1 (en) | 2001-05-15 | 2014-01-22 | Ortho-McNeil Pharmaceutical, Inc. | Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| US7220723B2 (en) | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| ITMI20011986A1 (it) | 2001-09-25 | 2003-03-25 | San Raffaele Centro Fond | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
| EP1453531B1 (de) | 2001-12-19 | 2008-05-14 | Alcedo Biotech GmbH | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren |
| US6923958B2 (en) | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
| US8133493B2 (en) | 2002-04-15 | 2012-03-13 | Washington University | Regulated attenuation of live vaccines to enhance cross-protective immunogenicity |
| US7495090B2 (en) | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
| US20040141948A1 (en) | 2002-11-20 | 2004-07-22 | Critical Therapeutics, Inc. | Use of HMGB fragments as anti-inflammatory agents |
| JP2006510619A (ja) | 2002-11-20 | 2006-03-30 | クリティカル セラピューティクス，インコーポレイテッド | 抗炎症剤としてのｈｍｇｂ断片の使用 |
| US20040156851A1 (en) | 2002-11-20 | 2004-08-12 | Critical Therapeutics, Inc. | HMGB1 combination therapies |
| EP1567544A4 (en) | 2002-11-20 | 2009-07-22 | Long Island Jewish Res Inst | USE OF HMGB POLYPEPTIDES TO IMPROVE THE IMMUNE REACTIONS |
| US20060014248A1 (en) | 2003-01-06 | 2006-01-19 | Xencor, Inc. | TNF super family members with altered immunogenicity |
| US20050181994A1 (en) | 2003-01-06 | 2005-08-18 | Xencor, Inc. | Novel variants of CD40L protein |
| US7696169B2 (en) | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| US7754209B2 (en) | 2003-07-26 | 2010-07-13 | Trubion Pharmaceuticals | Binding constructs and methods for use thereof |
| WO2005025604A2 (en) | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
| WO2005035570A2 (en) | 2003-10-10 | 2005-04-21 | Xencor, Inc. | Variants of cd40l protein |
| CA2548347A1 (en) | 2003-12-11 | 2005-06-30 | Sidney Kimmel Cancer Center | Methods for generating immunity to antigen |
| US8828957B2 (en) | 2003-12-11 | 2014-09-09 | Microvax, Llc | Methods for generating immunity to antigen |
| US20070128183A1 (en) | 2004-04-27 | 2007-06-07 | Intercell Ag | Td antigens |
| WO2005113598A2 (en) | 2004-05-21 | 2005-12-01 | Xencor, Inc. | Tnf super family members with altered immunogenicity |
| WO2006083301A2 (en) * | 2004-06-17 | 2006-08-10 | Medimmune, Inc. | Immunogenic compositions comprising hmgb1 polypeptides |
| WO2006012373A2 (en) | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
| US8513008B2 (en) | 2004-10-07 | 2013-08-20 | Argos Therapeutics, Inc. | Mature dendritic cell compositions and methods for culturing same |
| CN101080487B (zh) | 2004-10-07 | 2012-11-14 | 阿戈斯治疗公司 | 成熟树突细胞组合物及其培养方法 |
| GB0423681D0 (en) | 2004-10-26 | 2004-11-24 | Sec Dep For Environment Food & | Vaccine and nucleic acids |
| JP2008524261A (ja) | 2004-12-21 | 2008-07-10 | バクシネート コーポレーション | インフルエンザウイルスタンパク質の組成物およびその使用方法 |
| WO2006105972A1 (en) | 2005-04-07 | 2006-10-12 | Universite Libre De Bruxelles | Transgenic organism expressing cd40l and uses thereof |
| US20060286074A1 (en) | 2005-05-31 | 2006-12-21 | Yucheng Tang | Methods for immunotherapy of cancer |
| EP1909834A2 (en) | 2005-07-18 | 2008-04-16 | Critical Therapeutics, Inc. | Use of hmgb1 antagonists for the treatment of inflammatory skin conditions |
| PL1949913T3 (pl) | 2005-10-07 | 2010-10-29 | Proyecto De Biomedicina Cima S L | Immunostymulująca kombinacja do profilaktyki i leczenia wirusowego zapalenia wątroby typu c |
| CA2628837C (en) | 2005-11-07 | 2018-11-27 | Sidney Kimmel Cancer Center | Cd40 ligand fusion protein vaccine |
| WO2007054658A1 (en) | 2005-11-14 | 2007-05-18 | King's College London | Control of immune responses |
| WO2007130725A2 (en) * | 2006-02-06 | 2007-11-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of hmgb1 for protection against ischemia reperfusion injury |
| WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| US8802419B2 (en) | 2006-03-02 | 2014-08-12 | University Of Massachusetts | Modified pathogens for use as vaccines |
| EP2044198A4 (en) * | 2006-07-27 | 2010-09-08 | Ligocyte Pharmaceuticals Inc | CHIMERIC INFLUENZA VIRUS TYPE PARTICLES |
| US8564612B2 (en) * | 2006-08-04 | 2013-10-22 | Apple Inc. | Deep pixel pipeline |
| AU2007286161B2 (en) * | 2006-08-09 | 2013-05-02 | Medimmune, Llc | Influenza hemagglutinin and neuraminidase variants |
| US8604178B2 (en) | 2006-09-18 | 2013-12-10 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses |
| WO2008109825A2 (en) | 2007-03-08 | 2008-09-12 | Mayo Foundation For Medical Education And Research | Inducing immune-mediated tumor cell death |
| EP2152730A4 (en) * | 2007-05-02 | 2011-08-03 | Univ Emory | ENLARGEMENT OF GLYCOPROTEININCORPORATION IN VIRUSUAL PARTICLES |
| US9125854B2 (en) | 2007-10-30 | 2015-09-08 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods of enhancing immune responses to flagellated bacterium |
| PL3097926T3 (pl) | 2007-11-01 | 2020-04-30 | The Board Of Trustees Of The University Of Arkansas | Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria |
| HUE037157T2 (hu) | 2010-01-21 | 2018-08-28 | Univ Arkansas | Vakcinavektorok, és eljárások immunválaszok fokozására |
| WO2013071298A1 (en) | 2011-11-11 | 2013-05-16 | Nutrition Physiology Company, Llc | Lactic acid bacteria and their use as dietary supplementals for poultry |
| KR102008120B1 (ko) | 2010-06-09 | 2019-08-07 | 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 | 캄필로박터 감염을 감소시키기 위한 백신 및 방법 |
-
2011
- 2011-01-21 HU HUE11735230A patent/HUE037157T2/hu unknown
- 2011-01-21 DK DK11735230.2T patent/DK2525817T3/en active
- 2011-01-21 AU AU2011207331A patent/AU2011207331C1/en active Active
- 2011-01-21 MX MX2012008506A patent/MX341775B/es active IP Right Grant
- 2011-01-21 PL PL11735230T patent/PL2525817T3/pl unknown
- 2011-01-21 US US13/574,504 patent/US8956618B2/en active Active
- 2011-01-21 ES ES11735230.2T patent/ES2643646T3/es active Active
- 2011-01-21 EA EA201290675A patent/EA023058B1/ru not_active IP Right Cessation
- 2011-01-21 NO NO11735230A patent/NO2525817T3/no unknown
- 2011-01-21 CN CN201180006369.8A patent/CN102811734B/zh active Active
- 2011-01-21 JP JP2012550153A patent/JP6242050B2/ja active Active
- 2011-01-21 PT PT117352302T patent/PT2525817T/pt unknown
- 2011-01-21 EP EP11735230.2A patent/EP2525817B8/en active Active
- 2011-01-21 WO PCT/US2011/022062 patent/WO2011091255A1/en not_active Ceased
- 2011-01-21 CA CA2787661A patent/CA2787661C/en active Active
- 2011-01-21 UA UAA201210026A patent/UA110024C2/ru unknown
- 2011-01-21 KR KR1020127021697A patent/KR101638661B1/ko active Active
- 2011-01-21 NZ NZ601609A patent/NZ601609A/en not_active IP Right Cessation
-
2012
- 2012-07-19 CO CO12122137A patent/CO6561819A2/es not_active Application Discontinuation
- 2012-07-20 CL CL2012002016A patent/CL2012002016A1/es unknown
- 2012-08-02 ZA ZA2012/05824A patent/ZA201205824B/en unknown
-
2015
- 2015-02-16 US US14/623,105 patent/US9913893B2/en active Active
-
2016
- 2016-03-08 JP JP2016044306A patent/JP2016117757A/ja active Pending
-
2017
- 2017-12-05 JP JP2017233454A patent/JP6687585B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012002016A1 (es) | Vector para vacunas que comprende un polipeptido antigénico y un polipéptido hmgb1 o un fragmento funcional; composición que comprende el vector; método para potenciar respuesta inmune en un sujeto. | |
| ZA201308461B (en) | Multiple antigen presenting immunogenic composition and methods and uses thereof | |
| IL237522A0 (en) | Bioconjugates involving adapted antigens and their uses | |
| BR112015000530A2 (pt) | vacina de antígeno micobacteriano. | |
| BR112013018742A2 (pt) | cya-transportador de polipeptídeo(s) e use para induzir tanto as terapias e resposta imunitária profilática | |
| ZA201501639B (en) | Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same | |
| IN2014KN03063A (enExample) | ||
| CO6990668A2 (es) | Composiciones y métodos para anticuerpos que actúan sobre el factor p | |
| CL2012003299A1 (es) | Vacuna que comprende uno o mas antigenos, uno o mas oligonucleotidos inmunoestimuladores aislados y colesterol; metodo para inducir una respuesta inmune antigeno específica en un sujeto que necesita de la misma. | |
| EA201391183A1 (ru) | Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин | |
| BR112014033046A2 (pt) | linhagem mutante atenuada de salmonella typhi, vacina de dna e vacina de dna vxm01 | |
| HUE043473T2 (hu) | Fokozott immunválasz szarvasmarha fajokban | |
| EP3494989C0 (en) | COMPOSITE ANTIGEN SEQUENCES AND VACCINES | |
| BRPI0914782A2 (pt) | peptídeos de epítopos de cdca1 e vacinas contendo os mesmos | |
| EP2970947A4 (en) | RECOMBINANT HCV NS3 ANTIGENS AND THEIR MUTANTS FOR ENHANCED ANTIBODY DETECTION | |
| LT3173427T (lt) | Antikūnai prieš su inkstais susijusį antigeną 1 ir antigeną surišantys jų fragmentai | |
| PT2408913T (pt) | Péptidos neil3 e vacinas que incluem os mesmos | |
| IL245924A0 (en) | topk peptides and components comprising them | |
| CL2013001128A1 (es) | Composicion que comprende penflufeno y oxido de cobre y/o tiabendazol; y su uso para proteger la madera frente a basidiomicetos. | |
| EP2872530A4 (en) | KIF20A EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME | |
| ZA201103667B (en) | Rab6kifl/kif20a epitope peptide and vaccines containing the same | |
| EP2435567A4 (en) | CDC45L PEPTIDES AND VACCINES CONTAINING THEM | |
| IL226068B (en) | Tomm34 peptides and vaccines including the same | |
| BRPI1012312A2 (pt) | peptídeos vangl1 e vacinas incluindo os mesmos | |
| GB201120634D0 (en) | Adjuvant polypeptide |